Covidien has announced that PM100N, its Nellcor bedside SpO2 patient monitoring system, has been launched in Europe after receiving CE Mark approval.

It represents the only commercially available bedside pulse oximetry (SpO2) monitor featuring home care and sleep study modes that complies with established standards for medical electrical equipment used in home healthcare settings.

“Covidien has received European CE Mark approval for PM100N, its Nellcor bedside SpO2 patient monitoring system.“

Providing continuous monitoring of blood oxygenation and pulse rate, the device helps clinicians to detect and respond to dangerous respiratory events sooner, while patient trend data to makes it easier to evaluate a patient's clinical course.

Its Covidien-exclusive digital signal processing means that PM100N also offers industry-leading speed and accuracy, and reliable readings even during low patient perfusion, motion and other forms of signal interference.

Dr Scott Kelley, chief medical officer for respiratory and monitoring solutions at Covidien, said: "This new system includes all of the leading Nellcor technology that clinicians have trusted for more than 30 years, with additional features that make it well suited to the home healthcare environment."

This week, the company also received clearance from the US Federal Trade Commission for its planned merger with Medtronic.